



Chemotherapy Order Template™  
**Breast Cancer**  
**AC (DOXOrubicin/Cyclophosphamide) Every 21 Days**  
**→DOCEtaxel Every 21 Days + Trastuzumab**

**AC (DOXOrubicin/Cyclophosphamide) Every 21 Days Course**

**INDICATION:**

Adjuvant

**REFERENCES:**

1. [NCCN Clinical Practice Guidelines in Oncology™ Breast Cancer. V.1.2010.](#)
2. [Robert N, et al. J Clin Oncol. 2007; 25\(18S\):19647.<sup>B</sup>](#)

**NCCN SUPPORTIVE CARE:**

1. *Emetic Risk:* Day 1 High
2. *Fever Neutropenia Risk:* Intermediate

**CHEMOTHERAPY REGIMEN**

21-day cycle for 4 cycles

- **DOXOrubicin** 60 mg/m<sup>2</sup> IV Push on Day 1
- See *Safety Parameters and Special Instructions* for information on slow IV Push administration.
- **Cyclophosphamide** 600 mg/m<sup>2</sup> IV over 30 minutes on Day 1
- Oral hydration is strongly encouraged with cyclophosphamide; poorly hydrated patients may need supplemental IV hydration. Patients should attain combined oral and IV hydration of 2 – 3 L/day on day of chemotherapy. See *Other Supportive Therapy* for example of recommended hydration.

**This course is 4 cycles of AC (DOXOrubicin and cyclophosphamide) Every 21 Days. DOCEtaxel Every 21 Days and trastuzumab course is initiated following completion of this course. Please see Order Template BRS27b for DOCEtaxel Every 21 Days and trastuzumab course.**

**SUPPORTIVE CARE**

**Antiemetic therapy (See [www.nccn.org/professionals/physician\\_gls/PDF/antiemesis.pdf](http://www.nccn.org/professionals/physician_gls/PDF/antiemesis.pdf))**

Days 1 – 4

- 5-HT3 antagonist:  
Dolasetron 100 mg PO or 1.8 mg/kg IV or 100 mg IV Day 1  
OR  
Granisetron 2 mg PO daily or 1 mg PO BID or 0.01 mg/kg (maximum 1 mg) IV daily Day 1 or transdermal patch containing 34.3 mg granisetron applied 24 – 48 hours prior to first dose of chemotherapy; maximum duration of patch is 7 days  
OR  
Ondansetron 16 – 24 mg PO or 8 – 12 mg (maximum 32 mg/day) IV Day 1  
OR  
Palonosetron 0.25 mg IV Day 1  
**AND**
- Dexamethasone 12 mg PO/IV Day 1, then 8 mg PO/IV Days 2 – 4  
**AND**
- Aprepitant 125 mg PO or fosaprepitant 115 IV Day 1, aprepitant 80 mg PO Days 2 – 3
- Lorazepam 0.5 – 2 mg PO/IV or sublingual every 4 or every 6 hours as needed Days 1 – 4
- ± H<sub>2</sub> blocker or proton pump inhibitor

*Template continued on page 2*

NCCN Templates™ are peer-reviewed statements of the consensus of its authors derived from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) regarding their views of currently accepted approaches to treatment. An NCCN template does not constitute an order. Any clinician seeking to treat a patient using the NCCN Templates is expected to use independent medical judgment in the context of individual clinical circumstances of a specific patient's care or treatment. NCCN disclaims all warranties, express or implied including, without limitation, the implied warranties of merchantability and fitness for a particular purpose. NCCN does not warrant the accuracy, currency, or completeness of the NCCN Templates or make any representation regarding the use or the results of the use of the NCCN Templates in treatment. In no event shall NCCN or its members be liable for any damages including, without limitation, incidental, indirect, special, punitive, or consequential damages arising out of or in connection with the use of the NCCN Templates including, without limitation, loss of life, loss of data, loss of income or profit, losses sustained as a result of any injury to any person, or loss or damage to property or claims of third parties.



Chemotherapy Order Template™  
**Breast Cancer**  
**AC (DOXOrubicin/Cyclophosphamide) Every 21 Days**  
**→DOCEtaxel Every 21 Days + Trastuzumab**

**AC (DOXOrubicin/Cyclophosphamide) Every 21 Days Course**

page 2 of 2

**PRN for breakthrough:** Patients should be given at least one medication in a different category than that given above to have as needed for breakthrough. Please consult the NCCN Clinical Practice Guidelines in Oncology™ Antiemesis for appropriate antiemetic therapy.

**Myeloid growth factor therapy (See [www.nccn.org/professionals/physician\\_gls/PDF/myeloid\\_growth.pdf](http://www.nccn.org/professionals/physician_gls/PDF/myeloid_growth.pdf))**

CSFs not generally recommended as primary prophylaxis based on FN risk of chemotherapy regimen. For more information on prophylaxis of FN, refer to NCCN Clinical Practice Guidelines in Oncology™ Myeloid Growth Factors and [Appendix C](#) to the NCCN Chemotherapy Order Templates.

**Other Supportive Therapy**

- For cyclophosphamide: *Example of recommended hydration:* Sodium chloride 0.9% infused IV at a rate of 1.5 – 3 mL/kg/hour for a total of 500 mL on day of chemotherapy.

**MONITORING AND HOLD PARAMETERS**

- CBC with differential should be assessed routinely for potential dose evaluation.
- For DOXOrubicin:
  - DOXOrubicin is an anthracycline. Cumulative anthracycline dosage should be monitored.
  - Ejection fraction should be assessed prior to initiation of treatment and as clinically indicated.
  - Liver function should be assessed prior to each cycle for potential dose evaluation.
- For cyclophosphamide: Renal function should be assessed prior to each cycle for potential dose evaluation.

**SAFETY PARAMETERS AND SPECIAL INSTRUCTIONS**

- For DOXOrubicin:
  - **DOXOrubicin is a vesicant.**
  - This agent is administered IV Push. The preferred IV Push method for a vesicant is administration through the side port of a freely flowing IV; alternatively, the drug can be administered via direct IV push.
- For aprepitant and fosaprepitant: Refer to [Appendix D](#) for specific information regarding associated drug interactions.

NCCN Templates™ are peer-reviewed statements of the consensus of its authors derived from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) regarding their views of currently accepted approaches to treatment. An NCCN template does not constitute an order. Any clinician seeking to treat a patient using the NCCN Templates is expected to use independent medical judgment in the context of individual clinical circumstances of a specific patient's care or treatment. NCCN disclaims all warranties, express or implied including, without limitation, the implied warranties of merchantability and fitness for a particular purpose. NCCN does not warrant the accuracy, currency, or completeness of the NCCN Templates or make any representation regarding the use or the results of the use of the NCCN Templates in treatment. In no event shall NCCN or its members be liable for any damages including, without limitation, incidental, indirect, special, punitive, or consequential damages arising out of or in connection with the use of the NCCN Templates including, without limitation, loss of life, loss of data, loss of income or profit, losses sustained as a result of any injury to any person, or loss or damage to property or claims of third parties.